Vaccines for covid-19 patients

As part of the COVID-NMA initiative, we are identifying all randomized controlled trials (RCTs) of COVID-19 vaccine.

Below, you can access

Of note: For risk of bias assessment, we are considering the “effect of assignment to intervention” which might not be the analysis planned and reported by investigators. Consequently, when investigators planned to assess and report the “per-protocol” effect, the risk of bias for domain 2 may be evaluated as “some concerns”. We will contact investigators to obtain the results of the intent-to-treat analysis.

Treatment comparisons

We report below the forest plots for the main treatment comparisons.

Please choose a Treatment Comparison:

Last update: 22/01/2021

Trial Type Comparisons Design Participants Sample size Overall risk
of bias
Full description
Intervention 1 Intervention 2
NCT04412538
Institute of Medical Biology (IMB), Chinese Academy of Medical Sciences (CAMS).
Che Y,Clin Infect Dis,2020
Full text
Commentary
Inactivated virus KMS-1 100 EU D0/14 Adjuvant RCT
Phase 2
Healthy SARS-CoV-2 serology/DNA negative adults in two centres in China N=750
Some concerns
Details

Full description

KMS-1 150 EU D0/14 Adjuvant
KMS-1 100 EU D0/28 Adjuvant
KMS-1 150 EU D0/28 Adjuvant
NCT04471519 ; CTRI/2020/07/026300
Bharat Biotech
Ella R,medRxiv,2020
Full text
; Full text
Commentary
; Commentary
Inactivated virus 3mcg BBV152 + Algel-IMDG Adjuvant RCT
phase 1
Healthy SARS-CoV-2 serology/PCR negative adults in 11 centres in India N=375
Some concerns
Details

Full description

6mcg BBV152 + Algel-IMDG Adjuvant
6mcg BBV152 + Algel Adjuvant
NCT04412538
The Institute of Medical Biology (IMB), Chinese Academy of Medical Sciences (CAM)
Pu J, MedRxiv, 2020
Full text
Commentary
; Commentary
Inactivated virus KMS-1 D0/14 Adjuvant RCT
Phase 1
Healthy adults aged 18 to 59 years, SARS-CoV-2 nucleic acid or antibodies negative in a single centre in China. N=192
Some concerns
Details

Full description

KMS-1 D0/28 Adjuvant
ChiCTR2000031809
Wuhan Institute of Biological Products Co Ltd./Sinopharm
Xia S, JAMA, 2020
Full text
Commentary
Inactivated virus Inactivated 2.5mcg-D0/28/56 Adjuvant RCT
Phase 1/2
Healthy adults, aged 18 to 59 years, without history ofSARS-CoV(via on-site inquiry) or SARS-CoV-2 infection (via serologicaland nucleic acid test N=96
Low
Details

Full description

Inactivated 5mcg-D0/28/56 Adjuvant
Inactivated 10mcg-D0/28/56 Adjuvant
Inactivated 5mcg-D0/14 Adjuvant
Inactivated 5mcg-D0/21 Adjuvant
ChiCTR2000032459
Beijing Institute of Biological Products/Sinopharm
Xia S, Lancet Infect Dis, 2020
Full text
Commentary
Inactivated virus BBIBP-CorV 8mcg Adjuvant RCT
Phase 2
Healthy SARS-CoV-2 serology negative adults 18-59 years old and ?60 years old in a single centre in China N=112
Some concerns
Details

Full description

BBIBP-CorV 4mcg D0/14 Adjuvant
BBIBP-CorV 4mcg D0/21 Adjuvant
BBIBP-CorV 4mcg D0/28 Adjuvant
NCT04352608
Sinovac
Zhang Y,Lancet Infect Dis,2020
Full text
Commentary
Inactivated virus CoronaVac 3 mcg D0/14 Adjuvant RCT
Phase 2
Healthy SARS-CoV-2 serology/DNA negative adults in a single centre in China N=600
Some concerns
Details

Full description

CoronaVac 6 mcg D0/14 Adjuvant
CoronaVac 3 mcg D0/28 Adjuvant
CoronaVac 6 mcg D0/28 Adjuvant

The link in the column "Overall risk of bias" provides access to a complete description of the assessment of each risk of bias domain with supports for judgement produced using the Revised Cochrane risk-of-bias tool for randomized trials RoB 2.

The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review. The link in the column "Full description" provides access to the general characteristics of the study.

We acknowledge that we may have been unable to extract some information from pre-prints, as they represent preliminary forms of scientific communication.